FDAnews
www.fdanews.com/articles/72493-biotronik-announces-fda-approval-u-s-implant-of-xelos-dr-t-icd

Biotronik Announces FDA Approval, U.S. Implant of Xelos DR-T ICD

May 19, 2005

Biotronik has announced the FDA approval and first implant of a Xelos DR-T, the new high-energy implantable cardioverter defibrillator (ICD) that is part of a state-of-the-art system incorporating home monitoring early detection technology, biphasic II shock capability and 36-Joule shock energy.

Home monitoring with early detection technology allows physicians to remotely monitor ICD patients on a real-time basis and quickly intervene when necessary. Events are automatically transmitted from the ICD to the home monitoring website, which provides access to patient and device data anytime, from anywhere. Early detection technology immediately provides information on detection of arrhythmias, effectiveness of therapy and system status.

The company also announced that the first implantation of the Xelos DR-T was performed at Maricopa Medical Center in Phoenix by Chief of Cardiology Edgardo Zavala-Alarcon. "Biotronik's Xelos DR-T combines a higher delivered energy with the revolutionary Home Monitoring feature, so that I can monitor and manage my patients' advancing disease," Zavala-Alarcon said.